Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

883P - Preliminary study of a new antibody marker anti-EBV BNLF2b in screening population in high-incidence areas of nasopharyngeal carcinoma

Date

16 Sep 2021

Session

ePoster Display

Presenters

Mingfang Ji

Citation

Annals of Oncology (2021) 32 (suppl_5): S786-S817. 10.1016/annonc/annonc704

Authors

M. Ji1, T. Li2, F. Li1, X. Yu1, X. Guo2, B. Wu1

Author affiliations

  • 1 Cancer Research Institute, Zhongshan Hospital of Sun Yat-sen University, 528403 - Zhongshan/CN
  • 2 State Key Laboratory Of Molecular Vaccinology And Molecular Diagnostics, Xiamen University, 361102 - Xiamen/CN
More

Resources

Abstract 883P

Background

Nasopharyngeal carcinoma (NPC) is common in southern China. Despite being widely utilized, the positive predictive value (PPV) of the NPC screening scheme of China Ministry of Health based on two EBV IgA is still low. We have newly discovered a new type of anti-EBV antibody (BNLF2b-Ab), which significantly improved specificity in diagnosis of NPC, but its application value in population screening is still unclear.

Methods

We performed a prospective head-to-head comparative screening program in Zhongshan City of China. Participants were screened using EBNA1-IgA/VCA-IgA, and anti-BNLF2b in parallel. The testing algorithm of the first scheme cutoff values into two groups: Prob high-risk (above cutoff point) and Prob low-risk (below cutoff point). Cases screened with Prob high-risk or anti-BNLF2b positive were referred to otorhinolaryngologists for diagnostic workup. Comparison between the two schemes in early diagnosis rate, detection rate, PPV and negative predictive value (NPV) were analyzed.

Results

Among the 10340 participants recruited a total of 16 new NPC cases were diagnosed in the first year, of which 12 cases were in early stage (clinical phase I and II), and the early diagnosis rate reached 75% (12/16). Among the 16 diagnosed new cases, 12 and 16 cases of Prob high-risk and anti-BNLF2b positive were detected, respectively, which showed significant differences in detection rate (75.00% vs 100.00%, P=0.03). Also, PPV (3.46% vs 9.52%, P<0.001) and NPV (99.96% vs 100.00%, P=0.04) showed significant differences, respectively. There were 26 cases with double positive results of Prob high-risk and anti-BNLF2b, including 12 newly diagnosed cases, and the PPV reached 46.16%. In addition, anti-BNLF2b scheme reduced the false positive population by about 51.59% (179/347) without reducing the detection rate.

Conclusions

The new anti-BNLF2b scheme showed better efficacy than the two-IgA scheme in the preliminary analysis of population screening in NPC high-incidence area. Follow-up data in the next three to five years are needed for further verification and analysis.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Zhongshan Hospital of Sun Yat-sen University.

Funding

National Natural Science Foundation of China.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.